Generating impactful evidence of a drug life cycle
Generating evidence to meet the expectations of the people or entities that evaluate, prescribe or consume a drug is an obligation to optimize its value. This obligation allows us to optimize its development with regulators, its market access conditions with respect to payers, and its adoption by healthcare professionals and patients. Because this evidence generation process is addressing different stakeholders, it must involve the different components of a Pharma company: medical, commercial, market access, under the authority of the General Management.